Prognostic Nutritional Index Predicts Early Mortality in Diffuse Large B-cell Lymphoma
Yıl: 2022 Cilt: 37 Sayı: 1 Sayfa Aralığı: 85 - 91 Metin Dili: İngilizce DOI: 10.4274/MMJ.galenos.2022.87422 İndeks Tarihi: 23-06-2022
Prognostic Nutritional Index Predicts Early Mortality in Diffuse Large B-cell Lymphoma
Öz: Objective: The international prognostic index (IPI) and the revised
IPI (R-IPI) are used to determine the prognosis in diffuse large B-cell
lymphoma (DLBCL). However, these scoring systems are insufficient to
identify very high-risk patients. Recently, the prognostic nutritional index
(PNI) -calculated with lymphocyte count and albumin- has been used to
determine the prognosis in DLBCL. This study aimed to evaluate the effect
of PNI score on prognosis and survival in patients with high-risk DLBCL.
Methods: Patients diagnosed with DLBCL and treated with rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisolone were
included. Pre-treatment IPI, R-IPI, and PNI scores and progression-free
survival (PFS) and overall survival (OS) times were calculated. The cut-
off value for PNI according to OS was determined by using the X-Tile
program.
Results: One hundred and ten patients were included, the median age
was 63 years and the median follow-up period was 25 months. According
to R-IPI, the median OS could not be reached for the very good risk
group, and the median OS values were 83 and 17 months in the good and
poor-risk groups, respectively (p=0.001). The cohort was divided into
three groups according to the cut-off value for the PNI: patients with
PNI <33 were classified as high-risk, 33-42 intermediate-risk, and ≥42 as
low-risk. According to PNI, the median durations of PFS and OS were 2
months and 3 months in the high-risk group, 9 months and 19 months
in the intermediate-risk group respectively, and in the low-risk group the
median duration for PFS and OS could not be reached (p=0.001).
Conclusions: The R-IPI is widely used to estimate the prognosis in DLBCL.
But in our cohort, in the poor-risk patient group, the OS was 17 months
according to R-IPI, while this period was 3 months according to PNI. This
finding demonstrated that PNI might predict early mortality in DLBCL.
Anahtar Kelime: Prognostic Nutritional Index Predicts Early Mortality in Diffuse Large B-cell Lymphoma
Öz: Amaç: Diffüz büyük B-hücreli lenfomada (DBBHL) prognozu
belirlemede internasyonel prognostik indeks (IPI) ve revize edilmiş IPI
(R-IPI) kullanılmaktadır. Ancak bu skorlama sistemleri çok yüksek riskli
hastaları belirlemede yetersiz kalmaktadır. Son zamanlarda DBBHL’de
prognozu belirlemede lenfosit ve albümin ile hesaplanan prognostik
nutrisyonel indeks (PNİ) kullanılmaya başlanmıştır. Bu çalışmada amaç;
DBBHL’de yüksek riskli hastalarda PNİ skorunun prognoz ve sağkalıma
olan etkisini değerlendirmektir.
Yöntemler: Çalışmaya DBBHL tanısı konmuş ve rituksimab,
siklofosfamid, doksorubisin, vinkristin, prednizolon tedavisi almış
hastalar alındı. Tedavi öncesi IPI, R-IPI ve PNİ skorları ile progresyonsuz
sağkalım (PS) ve toplam sağkalım (TS) süreleri hesaplandı. TS’ye göre
PNİ için sınır değer X-Tile programı ile belirlendi.
Bulgular: Çalışmaya alınan 110 hastanın medyan yaşı 63, medyan takip
süresi 25 aydı. R-IPI’ya göre çok iyi riskli grup için medyan TS süresine
ulaşılamamışken, iyi ve kötü riskli gruplarda medyan TS sırası ile 83 ve 17
aydı (p=0,001). PNİ skoru için TS’de gruplar arasında fark yaratan sınır
değere göre kohort üç gruba ayrıldı: PNİ<33 olan hastalar yüksek riskli,
33-42 arası orta riskli, PNİ≥42 olan hastalar iyi riskli olarak sınıflandırıldı.
PNİ’ye göre medyan PS ve TS süreleri sırasıyla yüksek riskli grupta 2 ay
ve 3 ay, orta riskli grupta 9 ay ve 19 aydı, iyi riskli grupta PS ve TS için
medyan takip sürelerine ulaşılamadı (p=0,001).
Sonuçlar: DBBHL’de prognozu belirlemede R-IPI kullanılmaktadır,
fakat bizim kohortumuzda kötü riskli hasta grubunda R-IPI’ya
göre hesaplanan TS 17 ay iken PNİ’ye göre bu sürenin 3 ay olduğu
belirlenmiştir. Bu bulgu PNİ’nin erken mortaliteyi başarılı bir şekilde
öngörebileceğini göstermektedir.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265-76.
- 2. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-42.
- 3. Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021;384:842-58.
- 4. International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:987-94.
- 5. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857-61.
- 6. Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837-42.
- 7. Buzby GP, Mullen JL, Matthews DC, Hobbs CL, Rosato EF. Prognostic nutritional index in gastrointestinal surgery. Am J Surg. 1980;139:160-7.
- 8. Luan C, Wang F, Wei N, Chen B. Prognostic nutritional index and the prognosis of diffuse large b-cell lymphoma: a meta-analysis. Cancer Cell Int. 2020;20:455.
- 9. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7-33.
- 10. Niu JY, Tian T, Zhu HY, et al. Hyperfibrinogenemia is a poor prognostic factor in diffuse large B cell lymphoma. Ann Hematol. 2018;97:1841-9.
- 11. Bairey O, Shacham-Abulafia A, Shpilberg O, Gurion R. Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor. Hematol Oncol. 2016;34:184- 92.
- 12. Maurer MJ, Micallef IN, Cerhan JR, et al. Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. J Clin Oncol. 2011;29:1620-6.
- 13. Troppan KT, Schlick K, Deutsch A, et al. C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients. Br J Cancer. 2014;111:55-60.
- 14. Song MK, Chung JS, Seol YM, et al. Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy. Ann Oncol. 2010;21:140-4.
- 15. Luan CW, Tsai YT, Yang HY, et al. Pretreatment prognostic nutritional index as a prognostic marker in head and neck cancer: a systematic review and meta-analysis. Sci Rep. 2021;11:17117.
- 16. Periša V, Zibar L, Knezović A, Periša I, Sinčić-Petričević J, Aurer I. Prognostic nutritional index as a predictor of prognosis in patients with diffuse large B cell lymphoma. Wien Klin Wochenschr. 2017;129:411-9.
- 17. Yu W, Guo Q, Wang Z, et al. Clinical Significance of Prognostic Nutritional Index for Patients with Diffuse Large B-cell Lymphoma. Nutr Cancer. 2019;71:569-74.
- 18. Hao X, Wei Y, Wei X, et al. Glasgow prognostic score is superior to other inflammation-based scores in predicting survival of diffuse large B-cell lymphoma. Oncotarget. 2017;8:76740-8.
- 19. Zhou Q, Wei Y, Huang F, et al. Low prognostic nutritional index predicts poor outcome in diffuse large B-cell lymphoma treated with R-CHOP. Int J Hematol. 2016;104:485-90.
- 20. Luan C, Wu X, Zhang J, Chen B. Low Prognostic Nutritional Index Indicates Dismal Prognosis in Patients with Diffuse Large B Cell Lymphoma. Clin Oncol Res. 2020;3:1-8.
- 21. Soeters PB, Wolfe RR, Shenkin A. Hypoalbuminemia: Pathogenesis and Clinical Significance. JPEN J Parenter Enteral Nutr. 2019;43:181-93.
- 22. Talaulikar D, Choudhury A, Shadbolt B, Brown M. Lymphocytopenia as a prognostic marker for diffuse large B cell lymphomas. Leuk Lymphoma. 2008;49:959-64.
- 23. Kim DH, Baek JH, Chae YS, et al. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia. 2007;21:2227-30.
- 24. Porrata LF, Gertz MA, Inwards DJ, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood. 2001;98:579-85.
- 25. Porrata LF, Inwards DJ, Ansell SM, et al. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant. 2008;14:807-16.
- 26. Scott DW. Cell-of-Origin in Diffuse Large B-Cell Lymphoma: Are the Assays Ready for the Clinic? Am Soc Clin Oncol Educ Book. 2015:458-66.
- 27. Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood. 2011;117:2319-31.
APA | OZTURK E, ELIBOL T, KILICASLAN E, KABAYUKA B, OZUNAL I (2022). Prognostic Nutritional Index Predicts Early Mortality in Diffuse Large B-cell Lymphoma. , 85 - 91. 10.4274/MMJ.galenos.2022.87422 |
Chicago | OZTURK Erman,ELIBOL Tayfun,KILICASLAN Emrah,KABAYUKA Beyza,OZUNAL Isil ERDOGAN Prognostic Nutritional Index Predicts Early Mortality in Diffuse Large B-cell Lymphoma. (2022): 85 - 91. 10.4274/MMJ.galenos.2022.87422 |
MLA | OZTURK Erman,ELIBOL Tayfun,KILICASLAN Emrah,KABAYUKA Beyza,OZUNAL Isil ERDOGAN Prognostic Nutritional Index Predicts Early Mortality in Diffuse Large B-cell Lymphoma. , 2022, ss.85 - 91. 10.4274/MMJ.galenos.2022.87422 |
AMA | OZTURK E,ELIBOL T,KILICASLAN E,KABAYUKA B,OZUNAL I Prognostic Nutritional Index Predicts Early Mortality in Diffuse Large B-cell Lymphoma. . 2022; 85 - 91. 10.4274/MMJ.galenos.2022.87422 |
Vancouver | OZTURK E,ELIBOL T,KILICASLAN E,KABAYUKA B,OZUNAL I Prognostic Nutritional Index Predicts Early Mortality in Diffuse Large B-cell Lymphoma. . 2022; 85 - 91. 10.4274/MMJ.galenos.2022.87422 |
IEEE | OZTURK E,ELIBOL T,KILICASLAN E,KABAYUKA B,OZUNAL I "Prognostic Nutritional Index Predicts Early Mortality in Diffuse Large B-cell Lymphoma." , ss.85 - 91, 2022. 10.4274/MMJ.galenos.2022.87422 |
ISNAD | OZTURK, Erman vd. "Prognostic Nutritional Index Predicts Early Mortality in Diffuse Large B-cell Lymphoma". (2022), 85-91. https://doi.org/10.4274/MMJ.galenos.2022.87422 |
APA | OZTURK E, ELIBOL T, KILICASLAN E, KABAYUKA B, OZUNAL I (2022). Prognostic Nutritional Index Predicts Early Mortality in Diffuse Large B-cell Lymphoma. Medeniyet Medical Journal, 37(1), 85 - 91. 10.4274/MMJ.galenos.2022.87422 |
Chicago | OZTURK Erman,ELIBOL Tayfun,KILICASLAN Emrah,KABAYUKA Beyza,OZUNAL Isil ERDOGAN Prognostic Nutritional Index Predicts Early Mortality in Diffuse Large B-cell Lymphoma. Medeniyet Medical Journal 37, no.1 (2022): 85 - 91. 10.4274/MMJ.galenos.2022.87422 |
MLA | OZTURK Erman,ELIBOL Tayfun,KILICASLAN Emrah,KABAYUKA Beyza,OZUNAL Isil ERDOGAN Prognostic Nutritional Index Predicts Early Mortality in Diffuse Large B-cell Lymphoma. Medeniyet Medical Journal, vol.37, no.1, 2022, ss.85 - 91. 10.4274/MMJ.galenos.2022.87422 |
AMA | OZTURK E,ELIBOL T,KILICASLAN E,KABAYUKA B,OZUNAL I Prognostic Nutritional Index Predicts Early Mortality in Diffuse Large B-cell Lymphoma. Medeniyet Medical Journal. 2022; 37(1): 85 - 91. 10.4274/MMJ.galenos.2022.87422 |
Vancouver | OZTURK E,ELIBOL T,KILICASLAN E,KABAYUKA B,OZUNAL I Prognostic Nutritional Index Predicts Early Mortality in Diffuse Large B-cell Lymphoma. Medeniyet Medical Journal. 2022; 37(1): 85 - 91. 10.4274/MMJ.galenos.2022.87422 |
IEEE | OZTURK E,ELIBOL T,KILICASLAN E,KABAYUKA B,OZUNAL I "Prognostic Nutritional Index Predicts Early Mortality in Diffuse Large B-cell Lymphoma." Medeniyet Medical Journal, 37, ss.85 - 91, 2022. 10.4274/MMJ.galenos.2022.87422 |
ISNAD | OZTURK, Erman vd. "Prognostic Nutritional Index Predicts Early Mortality in Diffuse Large B-cell Lymphoma". Medeniyet Medical Journal 37/1 (2022), 85-91. https://doi.org/10.4274/MMJ.galenos.2022.87422 |